Aptinyx Inc
Aptinyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company is targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are focused on brain and nervous system. It has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder, and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated.